Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 q22026earningspressrelease.htm EX-99.1 Document Enovis Announces Second Quarter 2026 Results • Second-quarter sales growth of 3% on a reported basis, 5% organic • Second-quarter Reconstructive sales growth of 8% on a reported basis, 6% organic • Reaffirmed full-year 2026 guidance for reven
EX-99.1 2 q22026earningspressrelease.htm EX-99.1 Document Enovis Announces Second Quarter 2026 Results • Second-quarter sales growth of 3% on a reported basis, 5% organic • Second-quarter Reconstructive sales growth of 8% on a reported basis, 6% organic • Reaffirmed full-year 2026 guidance for revenue, adjusted EBITDA, adjusted EPS, and Free Cash Flow Conversion Dallas, TX, August 6, 2026 (GLOBE NEWSWIRE)—Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 3, 2026. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2026 Financial Results Enovis’ second-quarter net sales of $583 million grew 3% on a reported basis and 5% on an organic basis from the same quarter in 2025. Second...
Source
Exhibit EX-99.1
0001420800-26-000032
Filed August 6, 2026 at 10:19 AM UTC. The figures above are from the audited statements, not from this release.